Recombinant Human Antithrombin(rhAT)/Antithrombin Alfa

Specification

• Cat#: THP-0053
• Product Name: Recombinant Human Antithrombin(rhAT)/Antithrombin Alfa
• Description: Recombinant Human Antithrombin
• Sequences: HGSPVDICTA KPRDIPMNPM CIYRSPEKKA TEDEGSEQKI PEATNRRVWE LSKANSRFAT TFYQHLADSK NDNDNIFLSP LSISTAFAMT KLGACNDTLQ QLMEVFKFDT ISEKTSDQIH FFFAKLNCRL YRKANKSSKL VSANRLFGDK SLTFNETYQD ISELVYGAKL QPLDFKENAE QSRAAINKWV SNKTEGRITD VIPSEAINEL TVLVLVNTIY FKGLWKSKFS PENTRKELFY KADGESCSAS MMYQEGKFRY RRVAEGTQVL ELPFKGDDIT MVLILPKPEK SLAKVEKELT PEVLQEWLDE LEEMMLVVHM PRFRIEDGFS LKEQLQDMGL VDLFSPEKSK LPGIVAEGRD DLYVSDAFHK AFLEVNEEGS EAAASTAVVI AGRSLNPNRV TFKANRPFLV FIREVPLNTI IFMGRVANPC VK (Disulfide bridge: 8-128, 21-95, 247-430; Glycosylation site: 95, 135, 155, 192)
• Species: Human
• Molecular Weight: 49032.5271 Da
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 84720-88-7
• Formula: C2191H3451N583O656S18
• Endotoxin Level: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 1750U/ml
• Storage: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Pharmaceutical Information

• Pharmaceutical Application: Antithrombin Alfa
• Applications: The product is a recombinant antithrombin it is indicated for the prevention of peri-operative and peri-partum thromboembolic events in patients with hereditary deficiency of antithrombin.
• Examples of Clinical Use: Hereditary deficiency of antithrombin
• Pharmacodynamics: Hereditary antithrombin deficiency causes an increased risk of venous thromboembolism (VTE). In high risk situations, such as surgery or trauma or for pregnant women during the peri-partum period, the risk of development of VTEs is 10-50 times greater than the general population. In hereditary antithrombin deficient patients the product normalizes plasma antthrombin activity levels during peri-operative and peri-partum periods.
• Mechanism of action: Antithrombin is the main inhibitor of thrombin and Factor Xa , the serine proteases involved in blood coagulation. Antithrombin neutralizes the activity of thrombin and Factor Xa by forming a complex which is rapidly removed from the circulation.
• Affected organisms: Not Available
• Targets: Target 1. Prothrombin; Target 2. Coagulation factor X